The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2025
Synopsis
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
The global Rheumatoid Arthritis (RA) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rheumatoid Arthritis (RA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rheumatoid Arthritis (RA) Drugs.
Report Scope
The Rheumatoid Arthritis (RA) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rheumatoid Arthritis (RA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rheumatoid Arthritis (RA) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Segment by Type
NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rheumatoid Arthritis (RA) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
The global Rheumatoid Arthritis (RA) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Rheumatoid Arthritis (RA) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rheumatoid Arthritis (RA) Drugs.
Report Scope
The Rheumatoid Arthritis (RA) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rheumatoid Arthritis (RA) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rheumatoid Arthritis (RA) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Segment by Type
NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rheumatoid Arthritis (RA) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 NSAIDs
1.2.3 Analgesic Drugs
1.2.4 Corticosteroids
1.2.5 DMARDs
1.2.6 Biological Therapies
1.2.7 JAK-inhibitors
1.3 Market by Application
1.3.1 Global Rheumatoid Arthritis (RA) Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rheumatoid Arthritis (RA) Drugs Market Perspective (2019-2030)
2.2 Rheumatoid Arthritis (RA) Drugs Growth Trends by Region
2.2.1 Global Rheumatoid Arthritis (RA) Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Rheumatoid Arthritis (RA) Drugs Historic Market Size by Region (2019-2024)
2.2.3 Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Region (2025-2030)
2.3 Rheumatoid Arthritis (RA) Drugs Market Dynamics
2.3.1 Rheumatoid Arthritis (RA) Drugs Industry Trends
2.3.2 Rheumatoid Arthritis (RA) Drugs Market Drivers
2.3.3 Rheumatoid Arthritis (RA) Drugs Market Challenges
2.3.4 Rheumatoid Arthritis (RA) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue
3.1.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue (2019-2024)
3.1.2 Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Rheumatoid Arthritis (RA) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rheumatoid Arthritis (RA) Drugs Revenue
3.4 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Ratio
3.4.1 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rheumatoid Arthritis (RA) Drugs Revenue in 2023
3.5 Rheumatoid Arthritis (RA) Drugs Key Players Head office and Area Served
3.6 Key Players Rheumatoid Arthritis (RA) Drugs Product Solution and Service
3.7 Date of Enter into Rheumatoid Arthritis (RA) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Type
4.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Type (2019-2024)
4.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (2025-2030)
5 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Application
5.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Application (2019-2024)
5.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Rheumatoid Arthritis (RA) Drugs Market Size (2019-2030)
6.2 North America Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024)
6.4 North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rheumatoid Arthritis (RA) Drugs Market Size (2019-2030)
7.2 Europe Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024)
7.4 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size (2019-2030)
8.2 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rheumatoid Arthritis (RA) Drugs Market Size (2019-2030)
9.2 Latin America Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024)
9.4 Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size (2019-2030)
10.2 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Rheumatoid Arthritis (RA) Drugs Introduction
11.1.4 AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Rheumatoid Arthritis (RA) Drugs Introduction
11.2.4 Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Rheumatoid Arthritis (RA) Drugs Introduction
11.3.4 Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.3.5 Merck Recent Development
11.4 HEYL Chemisch-pharmazeutische Fabrik
11.4.1 HEYL Chemisch-pharmazeutische Fabrik Company Detail
11.4.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview
11.4.3 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Introduction
11.4.4 HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.4.5 HEYL Chemisch-pharmazeutische Fabrik Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Introduction
11.5.4 Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Detail
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Introduction
11.6.4 Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.6.5 Amgen, Inc. Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Rheumatoid Arthritis (RA) Drugs Introduction
11.7.4 Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.7.5 Pfizer Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Introduction
11.8.4 Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 UCB
11.9.1 UCB Company Detail
11.9.2 UCB Business Overview
11.9.3 UCB Rheumatoid Arthritis (RA) Drugs Introduction
11.9.4 UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.9.5 UCB Recent Development
11.10 GSK
11.10.1 GSK Company Detail
11.10.2 GSK Business Overview
11.10.3 GSK Rheumatoid Arthritis (RA) Drugs Introduction
11.10.4 GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.10.5 GSK Recent Development
11.11 Sanofi
11.11.1 Sanofi Company Detail
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Rheumatoid Arthritis (RA) Drugs Introduction
11.11.4 Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.11.5 Sanofi Recent Development
11.12 Abbott Laboratories
11.12.1 Abbott Laboratories Company Detail
11.12.2 Abbott Laboratories Business Overview
11.12.3 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Introduction
11.12.4 Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.12.5 Abbott Laboratories Recent Development
11.13 Teva Pharmaceutical
11.13.1 Teva Pharmaceutical Company Detail
11.13.2 Teva Pharmaceutical Business Overview
11.13.3 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Introduction
11.13.4 Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
11.13.5 Teva Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of NSAIDs
Table 3. Key Players of Analgesic Drugs
Table 4. Key Players of Corticosteroids
Table 5. Key Players of DMARDs
Table 6. Key Players of Biological Therapies
Table 7. Key Players of JAK-inhibitors
Table 8. Global Rheumatoid Arthritis (RA) Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Rheumatoid Arthritis (RA) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Rheumatoid Arthritis (RA) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Rheumatoid Arthritis (RA) Drugs Market Share by Region (2019-2024)
Table 12. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Rheumatoid Arthritis (RA) Drugs Market Share by Region (2025-2030)
Table 14. Rheumatoid Arthritis (RA) Drugs Market Trends
Table 15. Rheumatoid Arthritis (RA) Drugs Market Drivers
Table 16. Rheumatoid Arthritis (RA) Drugs Market Challenges
Table 17. Rheumatoid Arthritis (RA) Drugs Market Restraints
Table 18. Global Rheumatoid Arthritis (RA) Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Rheumatoid Arthritis (RA) Drugs Market Share by Players (2019-2024)
Table 20. Global Top Rheumatoid Arthritis (RA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rheumatoid Arthritis (RA) Drugs as of 2023)
Table 21. Ranking of Global Top Rheumatoid Arthritis (RA) Drugs Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Rheumatoid Arthritis (RA) Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Rheumatoid Arthritis (RA) Drugs Product Solution and Service
Table 25. Date of Enter into Rheumatoid Arthritis (RA) Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Rheumatoid Arthritis (RA) Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type (2019-2024)
Table 29. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type (2025-2030)
Table 31. Global Rheumatoid Arthritis (RA) Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application (2019-2024)
Table 33. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application (2025-2030)
Table 35. North America Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. AbbVie Company Detail
Table 51. AbbVie Business Overview
Table 52. AbbVie Rheumatoid Arthritis (RA) Drugs Product
Table 53. AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 54. AbbVie Recent Development
Table 55. Roche Company Detail
Table 56. Roche Business Overview
Table 57. Roche Rheumatoid Arthritis (RA) Drugs Product
Table 58. Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 59. Roche Recent Development
Table 60. Merck Company Detail
Table 61. Merck Business Overview
Table 62. Merck Rheumatoid Arthritis (RA) Drugs Product
Table 63. Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 64. Merck Recent Development
Table 65. HEYL Chemisch-pharmazeutische Fabrik Company Detail
Table 66. HEYL Chemisch-pharmazeutische Fabrik Business Overview
Table 67. HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Product
Table 68. HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 69. HEYL Chemisch-pharmazeutische Fabrik Recent Development
Table 70. Johnson & Johnson Company Detail
Table 71. Johnson & Johnson Business Overview
Table 72. Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Product
Table 73. Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 74. Johnson & Johnson Recent Development
Table 75. Amgen, Inc. Company Detail
Table 76. Amgen, Inc. Business Overview
Table 77. Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Product
Table 78. Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 79. Amgen, Inc. Recent Development
Table 80. Pfizer Company Detail
Table 81. Pfizer Business Overview
Table 82. Pfizer Rheumatoid Arthritis (RA) Drugs Product
Table 83. Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 84. Pfizer Recent Development
Table 85. Bristol-Myers Squibb Company Detail
Table 86. Bristol-Myers Squibb Business Overview
Table 87. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Product
Table 88. Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 89. Bristol-Myers Squibb Recent Development
Table 90. UCB Company Detail
Table 91. UCB Business Overview
Table 92. UCB Rheumatoid Arthritis (RA) Drugs Product
Table 93. UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 94. UCB Recent Development
Table 95. GSK Company Detail
Table 96. GSK Business Overview
Table 97. GSK Rheumatoid Arthritis (RA) Drugs Product
Table 98. GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 99. GSK Recent Development
Table 100. Sanofi Company Detail
Table 101. Sanofi Business Overview
Table 102. Sanofi Rheumatoid Arthritis (RA) Drugs Product
Table 103. Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 104. Sanofi Recent Development
Table 105. Abbott Laboratories Company Detail
Table 106. Abbott Laboratories Business Overview
Table 107. Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Product
Table 108. Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 109. Abbott Laboratories Recent Development
Table 110. Teva Pharmaceutical Company Detail
Table 111. Teva Pharmaceutical Business Overview
Table 112. Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Product
Table 113. Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2019-2024) & (US$ Million)
Table 114. Teva Pharmaceutical Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Rheumatoid Arthritis (RA) Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Rheumatoid Arthritis (RA) Drugs Market Share by Type: 2023 VS 2030
Figure 3. NSAIDs Features
Figure 4. Analgesic Drugs Features
Figure 5. Corticosteroids Features
Figure 6. DMARDs Features
Figure 7. Biological Therapies Features
Figure 8. JAK-inhibitors Features
Figure 9. Global Rheumatoid Arthritis (RA) Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Rheumatoid Arthritis (RA) Drugs Market Share by Application: 2023 VS 2030
Figure 11. Hospitals Case Studies
Figure 12. Clinics Case Studies
Figure 13. Others Case Studies
Figure 14. Rheumatoid Arthritis (RA) Drugs Report Years Considered
Figure 15. Global Rheumatoid Arthritis (RA) Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Rheumatoid Arthritis (RA) Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Rheumatoid Arthritis (RA) Drugs Market Share by Region: 2023 VS 2030
Figure 18. Global Rheumatoid Arthritis (RA) Drugs Market Share by Players in 2023
Figure 19. Global Top Rheumatoid Arthritis (RA) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rheumatoid Arthritis (RA) Drugs as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Rheumatoid Arthritis (RA) Drugs Revenue in 2023
Figure 21. North America Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Rheumatoid Arthritis (RA) Drugs Market Share by Country (2019-2030)
Figure 23. United States Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Rheumatoid Arthritis (RA) Drugs Market Share by Country (2019-2030)
Figure 27. Germany Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Share by Region (2019-2030)
Figure 35. China Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Rheumatoid Arthritis (RA) Drugs Market Share by Country (2019-2030)
Figure 43. Mexico Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Share by Country (2019-2030)
Figure 47. Turkey Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. AbbVie Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 50. Roche Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 51. Merck Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 52. HEYL Chemisch-pharmazeutische Fabrik Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 53. Johnson & Johnson Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 54. Amgen, Inc. Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 57. UCB Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 58. GSK Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 59. Sanofi Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 60. Abbott Laboratories Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 61. Teva Pharmaceutical Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2019-2024)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
